These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 20173718)

  • 1. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
    Baş B; Ozan B; Muğlali M; Celebi N
    Med Oral Patol Oral Cir Bucal; 2010 Jul; 15(4):e649-52. PubMed ID: 20173718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin for masseter hypertrophy.
    Al-Muharraqi MA; Fedorowicz Z; Al Bareeq J; Al Bareeq R; Nasser M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007510. PubMed ID: 19160335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin for masseter hypertrophy.
    Fedorowicz Z; van Zuuren EJ; Schoones J
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD007510. PubMed ID: 24018587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of unilateral masseter hypertrophy with botulinum toxin in two cases.
    Işeri M; Işeri PK
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(3-4):99-102. PubMed ID: 16010109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width.
    Wu WT
    Facial Plast Surg Clin North Am; 2010 Feb; 18(1):133-40. PubMed ID: 20206096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylcholine/deoxycholate lipolysis and hyaluronic acid augmentation to enhance nonsurgical lower facial contouring using botulinum toxin type A.
    Wong GR; Chen WP
    J Cosmet Dermatol; 2011 Jun; 10(2):159-62. PubMed ID: 21649822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy].
    Rijsdijk BA; van ES RJ; Zonneveld FW; Steenks MH; Koole R
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):529-32. PubMed ID: 9623101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle.
    Kim JH; Shin JH; Kim ST; Kim CY
    Plast Reconstr Surg; 2007 Feb; 119(2):711-7. PubMed ID: 17230111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A treatment for contouring of the lower face.
    Park MY; Ahn KY; Jung DS
    Dermatol Surg; 2003 May; 29(5):477-83; discussion 483. PubMed ID: 12752514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement.
    To EW; Ahuja AT; Ho WS; King WW; Wong WK; Pang PC; Hui AC
    Br J Plast Surg; 2001 Apr; 54(3):197-200. PubMed ID: 11254408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate.
    Kwon JS; Kim ST; Jeon YM; Choi JH
    Int J Oral Maxillofac Surg; 2009 Apr; 38(4):316-20. PubMed ID: 19231136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin for masseter reduction in Asian patients.
    Ahn J; Horn C; Blitzer A
    Arch Facial Plast Surg; 2004; 6(3):188-91. PubMed ID: 15148129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment.
    Xie Y; Zhou J; Li H; Cheng C; Herrler T; Li Q
    Plast Reconstr Surg; 2014 Aug; 134(2):209e-218e. PubMed ID: 25068343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy.
    Arikan OK; Tan FU; Kendi T; Koc C
    J Otolaryngol; 2006 Feb; 35(1):40-3. PubMed ID: 16527016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of botulinum toxin type A in masseter muscle hypertrophy: long-term effects and lasting improvement].
    Aydil B; Başaran B; Unsaler S; Süoğlu Y
    Kulak Burun Bogaz Ihtis Derg; 2012; 22(5):249-53. PubMed ID: 22991984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A.
    Gaofeng L; Jun T; Bo P; Bosheng Z; Qian Z; Dongping L
    J Plast Reconstr Aesthet Surg; 2010 Dec; 63(12):2026-31. PubMed ID: 20116356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The medical management of masseteric hypertrophy with botulinum toxin.
    Finn S; Ryan P; Sleeman D
    J Ir Dent Assoc; 2000; 46(3):84-6. PubMed ID: 11323940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Bae JH; Choi DY; Lee JG; Seo KK; Tansatit T; Kim HJ
    Dermatol Surg; 2014 Dec; 40(12):1334-9. PubMed ID: 25393348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.